Loading...
XNAS
CODX
Market cap2mUSD
Jul 09, Last price  
2.64USD
1D
0.00%
1Q
92.70%
IPO
-52.86%
Name

Co-Diagnostics Inc

Chart & Performance

D1W1MN
XNAS:CODX chart
P/E
P/S
4.73
EPS
Div Yield, %
Shrs. gr., 5y
7.34%
Rev. gr., 5y
-61.60%
Revenues
622k
-84.10%
010,00007,66239,911214,97474,552,75897,885,60334,218,2096,812,0383,915,160622,489
Net income
-47m
L+24.59%
-1,048,124-2,043,168-1,928,686-6,959,232-6,271,723-6,195,55742,478,52936,658,564-14,238,249-35,332,865-37,639,008-46,895,936
CFO
-29m
L-0.06%
-925,228-1,530,371-1,312,267-3,211,401-4,080,036-5,525,09128,165,23541,081,4246,568,737-22,081,865-29,155,045-29,136,927

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
IPO date
Jul 12, 2017
Employees
145
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT